Thursday, November 19, 2009

US Food and Drug Administration grants priority review for Actelion's miglustat in Niemann-Pick type C disease

19 November 2009 - Actelion Ltd announced today that a supplemental new drug application (sNDA) for an extension of indication for Zavesca® (miglustat) for the treatment of progressive neurological manifestations in adult and pediatric patients with Niemann-Pick type C disease (NP-C) has been accepted by the U.S. Food and Drug Administration (FDA).

The details can be read here.

No comments: